Development of neonatal-specific sequences for portable ultralow field magnetic resonance brain imaging: a prospective, single-centre, cohort study.

Intensive care Low field Magnetic resonance imaging Neonatal Portable

Journal

EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 26 01 2023
revised: 14 09 2023
accepted: 15 09 2023
medline: 18 12 2023
pubmed: 18 12 2023
entrez: 18 12 2023
Statut: epublish

Résumé

Magnetic Resonance (MR) imaging is key for investigation of suspected newborn brain abnormalities. Access is limited in low-resource settings and challenging in infants needing intensive care. Portable ultralow field (ULF) MRI is showing promise in bedside adult brain imaging. Use in infants and children has been limited as brain-tissue composition differences necessitate sequence modification. The aim of this study was to develop neonatal-specific ULF structural sequences and test these across a range of gestational maturities and pathologies to inform future validation studies. Prospective cohort study within a UK neonatal specialist referral centre. Infants undergoing 3T MRI were recruited for paired ULF (64mT) portable MRI by convenience sampling from the neonatal unit and post-natal ward. Key inclusion criteria: 1) Infants with risk or suspicion of brain abnormality, or 2) preterm and term infants without suspicion of major genetic, chromosomal or neurological abnormality. Exclusions: presence of contra-indication for MR scanning. ULF sequence parameters were optimised for neonatal brain-tissues by iterative and explorative design. Neuroanatomic and pathologic features were compared by unblinded review, informing optimisation of subsequent sequence generations in a step-wise manner. Main outcome: visual identification of healthy and abnormal brain tissues/structures. ULF MR spectroscopy, diffusion, susceptibility weighted imaging, arteriography, and venography require pre-clinical technical development and have not been tested. Between September 23, 2021 and October 25, 2022, 102 paired scans were acquired in 87 infants; 1.17 paired scans per infant. Median age 9 days, median postmenstrual age 40 On unblinded review, optimised portable MR can provide sufficient contrast, signal, and resolution for neuroanatomical identification and detection of a range of clinically important abnormalities. Blinded validation studies are now warranted. The Bill and Melinda Gates Foundation, the MRC, the Wellcome/EPSRC Centre for Medical Engineering, the MRC Centre for Neurodevelopmental Disorders, and the National Institute for Health Research (NIHR) Biomedical Research Centres based at Guy's and St Thomas' and South London & Maudsley NHS Foundation Trusts and King's College London.

Sections du résumé

Background UNASSIGNED
Magnetic Resonance (MR) imaging is key for investigation of suspected newborn brain abnormalities. Access is limited in low-resource settings and challenging in infants needing intensive care. Portable ultralow field (ULF) MRI is showing promise in bedside adult brain imaging. Use in infants and children has been limited as brain-tissue composition differences necessitate sequence modification. The aim of this study was to develop neonatal-specific ULF structural sequences and test these across a range of gestational maturities and pathologies to inform future validation studies.
Methods UNASSIGNED
Prospective cohort study within a UK neonatal specialist referral centre. Infants undergoing 3T MRI were recruited for paired ULF (64mT) portable MRI by convenience sampling from the neonatal unit and post-natal ward. Key inclusion criteria: 1) Infants with risk or suspicion of brain abnormality, or 2) preterm and term infants without suspicion of major genetic, chromosomal or neurological abnormality. Exclusions: presence of contra-indication for MR scanning. ULF sequence parameters were optimised for neonatal brain-tissues by iterative and explorative design. Neuroanatomic and pathologic features were compared by unblinded review, informing optimisation of subsequent sequence generations in a step-wise manner. Main outcome: visual identification of healthy and abnormal brain tissues/structures. ULF MR spectroscopy, diffusion, susceptibility weighted imaging, arteriography, and venography require pre-clinical technical development and have not been tested.
Findings UNASSIGNED
Between September 23, 2021 and October 25, 2022, 102 paired scans were acquired in 87 infants; 1.17 paired scans per infant. Median age 9 days, median postmenstrual age 40
Interpretation UNASSIGNED
On unblinded review, optimised portable MR can provide sufficient contrast, signal, and resolution for neuroanatomical identification and detection of a range of clinically important abnormalities. Blinded validation studies are now warranted.
Funding UNASSIGNED
The Bill and Melinda Gates Foundation, the MRC, the Wellcome/EPSRC Centre for Medical Engineering, the MRC Centre for Neurodevelopmental Disorders, and the National Institute for Health Research (NIHR) Biomedical Research Centres based at Guy's and St Thomas' and South London & Maudsley NHS Foundation Trusts and King's College London.

Identifiants

pubmed: 38106560
doi: 10.1016/j.eclinm.2023.102253
pii: S2589-5370(23)00430-3
pmc: PMC10725077
doi:

Types de publication

Journal Article

Langues

eng

Pagination

102253

Investigateurs

Sean C Deoni (SC)
Emil Ljungberg (E)
Carly Bennallick (C)
Shannon Kolind (S)
Doug Dean (D)
Michael S Pepper (MS)
Lydia Sekoli (L)
Alexica De Canha (A)
Jeanne Van Rensburg (J)
Derek K Jones (DK)
Niall Bourke (N)
Hemmen Sabir (H)
Samson Lecurieux Lafayette (S)

Informations de copyright

© 2023 The Author(s).

Déclaration de conflit d'intérêts

PC is supported by the Medical Research Council Centre for Neurodevelopmental Disorders [MR/N026063/1] to undertake this work and received an educational stipend from ISMRM to attend the international ISMRM conference and present this work. FP was employed by the Guy′s & St. Thomas′ NHS Foundation Trust & King’s College London as a senior MR physicist at study outset, during experimental design and initial participant recruitment, he is now a senior clinical scientist employed by Hyperfine Inc., since May 2022–drawing a salary, shares and stock options. RT is an MR sequence developer employed by Hyperfine Inc., and is a holder of shares and stock option of Hyperfine Inc. JOM has institutional funding from the Bill & Melinda Gates Foundation Consortium grant to support research work by his group in neurodevelopment, including data from conventional 3T MRI and Hyperfine scanners–this grant is focused on image analysis and is not commercially sponsored. SW has received funding from the Bill & Melinda Gates Foundation for attendance and travel to sites for training and knowledge exchange during the development and delivery of this project. TA is supported by the UK MRC for a Translational support fellowship [MR/V036874/1] for personal salary, and funding for 3T MRI scans, the MRC Centre for Neurodevelopmental Disorders, King’s College London [MR/N026063/1] for administrative support, funding, and a Clinician Scientist Fellowship [MR/P008712/1]—for personal salary and funding for 3T MRI scans. TA is supported by the EPSRC UK Network grant, co-investigator [EP/W035154/1]. DE and JVH: The Hyperfine machine (Swoop® MR System) was provided by the Bill and Melinda Gates Foundation as part of the Unity Consortium.

Auteurs

Paul Cawley (P)

Centre for the Developing Brain, School of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 7EH, UK.
Neonatal Intensive Care Unit, Evelina Children's Hospital London, St Thomas' Hospital, 6th Floor North Wing, Westminster Bridge Road, London SE1 7EH, UK.
MRC Centre for Neurodevelopmental Disorders, King's College London, London SE1 1UL, UK.

Francesco Padormo (F)

Centre for the Developing Brain, School of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 7EH, UK.
Medical Physics, Guy's & St. Thomas' NHS Foundation Trust, London, UK.
Hyperfine, Inc., 351 New Whitfield St., Guilford, Connecticut 06437, USA.

Daniel Cromb (D)

Centre for the Developing Brain, School of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 7EH, UK.
Neonatal Intensive Care Unit, Evelina Children's Hospital London, St Thomas' Hospital, 6th Floor North Wing, Westminster Bridge Road, London SE1 7EH, UK.

Jennifer Almalbis (J)

Centre for the Developing Brain, School of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 7EH, UK.
Neonatal Intensive Care Unit, Evelina Children's Hospital London, St Thomas' Hospital, 6th Floor North Wing, Westminster Bridge Road, London SE1 7EH, UK.

Massimo Marenzana (M)

Centre for the Developing Brain, School of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 7EH, UK.

Rui Teixeira (R)

Hyperfine, Inc., 351 New Whitfield St., Guilford, Connecticut 06437, USA.

Alena Uus (A)

Centre for the Developing Brain, School of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 7EH, UK.

Jonathan O'Muircheartaigh (J)

Centre for the Developing Brain, School of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 7EH, UK.
MRC Centre for Neurodevelopmental Disorders, King's College London, London SE1 1UL, UK.
Department of Forensic and Neurodevelopmental Science, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Steven C R Williams (SCR)

Centre for Neuroimaging Sciences, King's College London, De Crespigny Park, London SE5 8AF, UK.

Serena J Counsell (SJ)

Centre for the Developing Brain, School of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 7EH, UK.

Tomoki Arichi (T)

Centre for the Developing Brain, School of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 7EH, UK.
MRC Centre for Neurodevelopmental Disorders, King's College London, London SE1 1UL, UK.
Paediatric Neurosciences, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London SE1 7EH, UK.

Mary A Rutherford (MA)

Centre for the Developing Brain, School of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 7EH, UK.
MRC Centre for Neurodevelopmental Disorders, King's College London, London SE1 1UL, UK.

Joseph V Hajnal (JV)

Centre for the Developing Brain, School of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 7EH, UK.

A David Edwards (AD)

Centre for the Developing Brain, School of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 7EH, UK.
Neonatal Intensive Care Unit, Evelina Children's Hospital London, St Thomas' Hospital, 6th Floor North Wing, Westminster Bridge Road, London SE1 7EH, UK.
MRC Centre for Neurodevelopmental Disorders, King's College London, London SE1 1UL, UK.

Classifications MeSH